High frequency ultrasound assessment of systemic sclerosis skin involvement: intra-observer repeatability and relationship with clinician assessment and dermal collagen content

Victoria A Flower, Shaney L Barratt, Darren J Hart, Amanda B Mackenzie, Jacqueline A Shipley, Stephen G Ward, John D Pauling

Research output: Contribution to journalArticlepeer-review

20 Citations (SciVal)

Abstract

Objective. The modified Rodnan skin score (mRSS) remains the preferred method for skin assessment in systemic sclerosis (SSc). There are concerns regarding high interobserver variability of mRSS and negative clinical trials utilizing mRSS as the primary endpoint. High-frequency ultrasound (HFUS) allows objective assessment of cutaneous fibrosis in SSc. We investigated the relationship between HFUS with both mRSS and dermal collagen. Methods. Skin thickness (ST), echogenicity, and novel shear wave elastography (SWE) were assessed in 53 patients with SSc and 15 healthy controls (HCs) at the finger, hand, forearm, and abdomen. The relationship between HFUS parameters with mRSS (n = 53) and dermal collagen (10 patients with SSc and 10 HCs) was investigated. Intraobserver repeatability of HFUS was calculated using intraclass correlation coefficients (ICCs). Results. HFUS assessment of ST (hand/forearm) and SWE (finger/hand) correlated with local mRSS at some sites. Subclinical abnormalities in ST, echogenicity, and SWE were present in clinically uninvolved SSc skin. Additionally, changes in echogenicity and SWE were sometimes apparent despite objectively normal ST on HFUS. ST, SWE, and local mRSS correlated strongly with collagen quantification (r = 0.697, 0.709, 0.649, respectively). Intraobserver repeatability was high for all HFUS parameters (ICCs for ST = 0.946-0.978; echogenicity = 0.648-0.865; and SWE = 0.953-0.973). Conclusion. Our data demonstrate excellent reproducibility and reassuring convergent validity with dermal collagen content. Detection of subclinical abnormalities is an additional benefit of HFUS. The observed correlations with collagen quantification support further investigation of HFUS as an alternative to mRSS in clinical trial settings.

Original languageEnglish
Pages (from-to)867-876
Number of pages10
JournalThe Journal of Rheumatology
Volume48
Issue number6
Early online date1 Nov 2020
Publication statusPublished - 1 Jun 2021

Bibliographical note

Publisher Copyright:
Copyright © 2021. All rights reserved.

Funding

This work was supported by Scleroderma & Raynaud’s UK. 1V.A. Flower, Consultant Rheumatologist, MBBS, PhD, J.D. Pauling, Consultant Rheumatologist and Senior Lecturer, BMBS, PhD, Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Royal United Hospitals NHS Foundation Trust, Bath, Department of Pharmacy and Pharmacology, University of Bath, Bath; 2S.L. Barratt, BMBS, PhD, Department of Respiratory Medicine, North Bristol NHS Trust, Bristol, Academic Respiratory Unit, School of Clinical Sciences, University of Bristol, Bristol; 3D.J. Hart, Clinical Scientist, PhD, J.A. Shipley, Clinical Scientist, PhD, Clinical Measurement and Imaging Department, Royal National Hospital for Rheumatic Diseases, Royal United Hospitals NHS Foundation Trust, Bath; 4A.B. Mackenzie, Senior Lecturer, PhD, Department of Pharmacy and Pharmacology, University of Bath, Bath; 5S.G. Ward, Professor, PhD, Centre for Therapeutic Innovation & Department of Pharmacy and Pharmacology, University of Bath, Bath, UK. JDP has received speaker’s honoraria and research grant support (> $10,000) from Actelion Pharmaceuticals and has undertaken consultancy work for Actelion Pharmaceuticals and Boehringer Ingelheim. SLB has received educational support and has undertaken consultancy work for Boehringer Ingelheim. ABM has received funding from UCB, Janssen, and Pfizer; and holds shares in Ikusda Therapeutics. SGW has received funding from UCB, Pfizer, Novartis, GSK, and Boehringer Ingelheim. VAF, DJH, and JAS have no conflicts of interests. Address correspondence to Dr. V.A. Flower, The Royal National Hospital for Rheumatic Diseases, Royal United Hospitals NHS Foundation Trust, Combe Park, Bath, BA1 3NG, UK. Email: [email protected]. Accepted for publication October 16, 2020.

FundersFunder number
Ikusda Therapeutics
Pfizer
GlaxoSmithKline
Novartis
Actelion Pharmaceuticals
Boehringer Ingelheim Ltd
Janssen Pharmaceutica NV
UCB
Scleroderma and Raynaud's UK

    Keywords

    • Collagen
    • Skin
    • Systemic sclerosis
    • Ultrasonography

    ASJC Scopus subject areas

    • Immunology and Allergy
    • Rheumatology
    • Immunology

    Fingerprint

    Dive into the research topics of 'High frequency ultrasound assessment of systemic sclerosis skin involvement: intra-observer repeatability and relationship with clinician assessment and dermal collagen content'. Together they form a unique fingerprint.

    Cite this